The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

The Food and Drug Administration is considering pulling its authorization of Pfizer’s COVID-19 vaccine for healthy children ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

Research and Development Expenses-- $4,700,000 compared to $5,600,000 during the prior year comparable period. Kodiak PCR ...

The Trump administration’s COVID-revenge campaign has laid the groundwork for Kennedy’s larger agenda.

Robert F. Kennedy Jr.’s ‘Make America Healthy Again’ movement is taking off in red — and blue — states, even as health ...

With the latest COVID-19 surge, information on testing and vaccinations for those who are uninsured is becoming hard to find.

PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-yearInvivyd’s target of near-term profitability (1H 2025) was not met but remains ...

Diagnostics' progress on their PCR platform, with key trials in 2025 and commercialization plans by 2026, targeting U.S. and global markets.

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Key Points GAAP revenue jumped 413% year over year to $11.8 million in Q2 2025, but fell far short of analyst estimates, with GAAP revenue of $11.8 million missing the consensus of $23.2 million by 49 ...

Invivyd (IVVD) has received and is aligned with advice from the FDA on a compact and, therefore, rapid pathway to potential Biologics License ...